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Molecular Imaging (MI) techniques are rapidly developed to achieve precise, early and in-time 
diagnosis for various disease. Unlike conventional anatomical imaging technique, non-invasive 
molecular imaging has paved a novel way for disease study and diagnosis on a molecular level in 
living organism without intervention on its biological process. Molecular imaging can allow 
clinicians to gain more information on precise localization, visualization of the disease. One 
strategy to visualize certain disease is to target biomarker on certain cells by designed substrate 
specific imaging probe.  
 
Tumor necrosis factor (TNF) - related apoptosis-inducing ligand, known as TRAIL, is a 
promising anticancer ligand that can biologically bind to Death Receptor 5 (DR5). Studies have 
showed that colorectal cancers have significant DR5 upregulation. Except in oncology, liver 
fibrosis is also relevant to TRAIL, which is a common chronic liver disease that will lead to liver 
cirrhosis and hepatocellular carcinoma. Activated hepatic stellate cells (aHSCs) is major 
abnormal cell types, while studies show aHSCs are associated with elevated expression of death 
receptors and sensitivity towards TRAIL induced cell death. In this study, five phage-display 
determined Death Receptor 5 (DR5) targeted peptide has been developed to visualize DR5 and 
apoptosis simultaneously.  
 
In the initial stage of developing Death Receptor 5 based PET or SPECT imaging agent for 
living cirrhosis, fluorescent dye, 5-carboxyfluorescent, has been conjugated on the peptide for 
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Chapter 1: Chemistry of Molecular Imaging  
Background  
Molecular imaging has been emerged as a powerful tool for disease diagnosis on a cellular and 
molecular level without any interference on its physiological process. Therefore, it is prevalent to 
use molecular imaging technique to monitor or diagnose disease stage. Based on different 
imaging mechanism, different imaging techniques have been developed for imaging. Unlike 
traditional imaging techniques such as CT and MRI which are based on tissue difference, 
molecular imaging escalates the precision into designing the imaging probe on a molecular level. 
The ultimate goal of molecular imaging is to localize disease noninvasively and to quantify 
certain molecular events within living organism [1]. What is new for molecular imaging 
nowadays is that it brings the correlation between molecule and anatomic information. It leads to 
image-guided molecular therapy and imaging simultaneously. And biomarkers will be utilized to 
offer imaging and quantification evidence for early disease diagnosis. Molecular imaging is an 
interdisciplinary topic that involves with multiple subjects such as mathematics, signal 





Figure 1.1. Key steps involving in studying molecular imaging [2] 
When applying molecular imaging into disease diagnosis, the first step is to identify a 
pathological path of interest, and to assess the significance of imaging this process by molecular 
imaging. The second step is to identify a molecular target that will distinguish itself from other 
biomarkers which will take a pivotal role in imaging this pathological biochemical process. In 
this step, a selection of appropriate imaging modalities is also decided. After that, chemists and 
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radiochemists are working together to design and synthesize the radiotracer to specifically target 
the biomarker. Then a number of in vitro and in vivo biology-based tests will be conducted to 
evaluate the imaging agent based on specificity and selectivity. If the radiotracer’s final goal is to 
get FDA approval, it will undergo clinical studies and put it into clinical practice. 
1.1 Molecular Imaging Techniques  
1.1.1 Positron Emission Tomography (PET) 
One of the most commonly used imaging technique which is the most sensitive method in 
nuclear medicine is Positron Emission Tomography (PET). Positron-emitting radionuclide will 
be used in this imaging technique, when it decays, two 511keV γ- rays will be produced resulting 
from the annihilation of the positron emitting from the radionuclide and a surrounding electron in 
our body. Radionuclides can be incorporated into metabolically active molecules to monitor 
biological process. When a radionuclide undergoes positron emission decay, the tissue 
penetration for the positron is ~2mm then they are detected by PET scanner to further process the 















Figure 1.2 A simplified small animal PET imaging procedure [2] 
 
 
PET possesses high sensitivity which is useful in early disease diagnosis such as cancer and 
central nervous disease, which will start pathologic change at the cellular level. Radiotracer can 
take active participation in the physiological process. There are many radioactive tracers to 
choose from based on their half-lives. When the radiotracer is intravenously injected into the 
















1.1.2 Single Photon Emission Computed Tomography (SPECT) 
Similar to PET, Single Photon Emission Computed Tomography (SPECT) is another nuclear 
imaging technique that uses radionuclides as imaging moieties. Unlike PET, the radionuclides 
for SPECT imaging only involves a single γ ray signal rather than a two way signals based on its 
decay mode. When a radionuclide decays, apart from generating gamma ray, it also produces 
alpha and beta radiation. For instance, technetium-99 (99mTc), is a common radionuclide for 
SPECT imaging. The excited nuclear state is more stable than the average excited states after 
releasing β particle, therefore the daughter nucleus forms a metastable state, 99mTc, which is a 
nuclear isomer that has a half-life around 6 hours before it transits to 99Tc, a process that will 
emit γ ray [4]. The other commonly used SPECT radionuclides are iodinated group radioisotopes 
such as 123I, 125I and 131I.  
Nuclide Half-life (in hour) Decay Mode 
11C 0.34 β+ 
18F 1.83 β+(97%) 
64Cu 12.7 β+(18%);  β-(37%); EC(24%) 
68Ga 1.14 β+(89%); EC(17%) 
86Y 14.7 β+(33%); EC (67%) 
124I 100.2 β+(23%); EC (77%) 




Figure 1.3 Scheme for 99mTc formation and decay mode [4] 
1.1.3 Magnetic Resonance Imaging (MRI) 
Magnetic Resonance Imaging (MRI) is a non-invasive imaging technique which is based on 
nuclear magnetic resonance (NMR) providing anatomical and physiological information on its 
image. It will give spatial distribution of the intensity of the proton in the body [5], which is a 
widely used clinical imaging technique. All the proton spins can generate a small magnet charge, 
when the human body is exposed under the external magnetic field, the protons align with that 
field. The MRI technicians introduce a radiofrequency pulse which will alter the alignment of 
protons into 90 degree or 180 degrees. Once the pulse is off, the proton will realign with the 
magnetic field and release electromagnetic energy along the way. MRI scanner will detect the 
energy signal and differentiate various tissues in human body.  
 
When we classified the contrast agents, three parameters need to be taken into consideration. 
Proton density (ρ), longitudinal relaxation time T1 and transverse relaxation times T2 and T2* 
[6]. 
To better visualize the difference between diseased tissue and normal tissue, contrast agent has 
been utilized to enhance the imaging contrast after administration into the body. When agents 
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accumulate, it will increase the relaxation rates of water protons. Other classification category 
depends on the materials used, based on paramagnetic, superparamagnetic and ferromagnetic 
materials. 
  
1.1.4 CEST MRI imaging 
Chemical Exchange Saturation Transfer (CEST) contrast agents have paved a new approach to 
target biomarker through molecular imaging. The difficulties for using MRI technique as an 
imaging method is tackled by CEST imaging. The inherent low detection sensitivity restricts its 
contrast agent concentration to around 10 μM – 10mM, therefore the biomarker concentration in 
vivo is higher than this level. Furthermore, increasing number of researches show that the 
metallic exogenous contrast agents could alter the cell behavior as well as eliciting cell death [7]. 
CEST is a relatively new MRI imaging technique which the compounds contain exchangeable 
protons or exchangeable molecules that can be detected indirectly through water molecules with 
enhanced sensitivity. The mechanism is very simple: when a radiofrequency (RF) irradiates 
through exchangeable solute protons which have a different specific frequency resonance than 
water protons, those exchangeable protons are selectively saturated. Then the saturation is 
transferred to bulk water when the solute protons exchange with the water protons leading to 
slight water signal attenuation. In this case, the number of water protons are larger than the 
number of saturation solute protons. The exchanging process happens repetitively with the 
unsaturated water protons to prolong the irradiation, allowing the indirect imaging of low 




Figure 1.4 principle and measurement approach for CEST [8] 
The figure showed above is a simple explanation on the CEST. Amide protons are saturated at 
specific resonance frequency in the proton spectrum (8.25 ppm), then this saturation is 
transferred to water (4.75 ppm) at exchange rate Ksw, since the process is a dynamic 
equiliubrium, when the exchange process undergoes a saturation time, the effect becomes visible 
on water signals like the diagram (b, right).  
CEST is the most suitable for molecular and cellular imaging based on different magnetic 
speices from paramagnetic to diamagnetic species, leading to ParaCEST [9] and DiaCEST [10]. It 
also can be classified via proton exchange type. First is the proton exchange type, amine, amide 
and hydroxyl protons and most diamagnetic CEST compounds belong to this group (a). The 
second is the molecular exchange type. For instance, in a ParaCEST agent, a water molecule 
cooordinated to Europium, this type of molecular exchange is faster than proton-proton exchange 
(b). The last catergory is the compartment exchange, as illustrated in the c diagram below, the 





Figure 1.5 Classification of CEST contrast agent based on exchange type [9] 
 
1.2 PET/SPECT imaging in Central Nervous Disease 
The human brain is the most complex organ which acts as the center of the nervous system. It is 
very vulnerable to central nervous system (CNS) diseases such as neurodegenerative disorders 
including Alzheimer’s disease (AD), Parkinson’s disease (PD) and multiple sclerosis and 
susceptible to psychiatric conditions including schizophrenia and depression [10]. However, 
studying the brain is not an easy research to conduct.  
PET can be used to explore the human brain disorders and diseases. A normal brain needs to 
consume large quantity of glucose, however, in a pathological brain of AD, the metabolism of 
glucose as well as oxygen will significantly decrease. 2-deoxy-2-[fluorine-18] fluoro- D-glucose, 
known as [18F] FDG, is a radiofluorinated glucose analog which is widely used in cancer 
imaging. It is a glucose analog that is closely related to glucose metabolism in various organs. 
When [18F] FDG is taken up by cells, phosphorylated by hexokinase which is highly elevated in 
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growing malignant tumor cells [11], therefore it’s a useful imaging tracer associated with glucose 
metabolic activity. In central nervous disease, the [18F] FDG may be an effective marker to 
successfully identify the AD and to make early diagnosis with frontotemporal dementia [12]. 
The difficulty of exogenous imaging tracer to image the brain is limited by a tissue called blood 
brain barrier (BBB). Blood brain barrier is a highly selective membrane that can separate the 
circulating blood from brain and extracellular fluid from the central nervous system. It is a tissue 
formed by brain endothelial cells and only allows water, some gases and lipid-soluble molecules 
to pass, preventing the neurotoxic materials to get into the brain [13].  
One of the most successful PET imaging of amyloid in AD is [11C]-PIB, which is the first 
radiotracer that was put into human trial study. Researchers in university of Pittsburg reports the 
first human study of amyloid-imaging tracer for Alzheimer’s Disease. In this study, AD patients 
show a marked retention of [11C]-PIB in the area of cortex associated with amyloid deposits.  






Figure 1.6 standard uptake value of PIB and FDG; PIB retention area [14] 
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The [11C]-PIB standard uptake value (SUV) clearly illustrates retention compared with the 
healthy patient. While the healthy patient has FDG retention, high PIB retention in the frontal 
and temporoparietal cortices of the AD patient [14]. 
 
1.3 Prostate Specific Membrane Antigen (PSMA) targeted imaging  
Prostate Specific Membrane Antigen (PSMA), also known as glutamate carboxypeptidase II 
(GCPII), N-acetyl-L-aspartyl-L-glutamate peptidase I or NAAG peptidase, is a type II 
transmembrane protein with elevated expression on prostate cancer cells. PSMA is the most 
prostate-specific cell membrane antigen known, which is present in nearly 95% of prostate 
cancer disease cases. And it will generally increase in expression when prostate cancer 
progresses. Therefore, it has made itself a useful target for prostate cancer molecular imaging.  
 
The small molecule inhibitor of PSMA is zinc binding compounds attached to a glutamate or 
glutamate isostere and the most commonly used chemical structure for targeting PSMA is Lys-
Glu-urea as targeting scaffold. The most commonly studied PSMA targeting imaging tracer is 
based on this scaffold with appropriate chemical modification: 1) to improve its binding affinity; 
2) to modify its pharmacokinetic properties 3) to chelate radiometals or conjugate prosthetic 
group onto the radiotracers as imaging moiety. For PSMA-targeting agent, antibodies and small 
molecules are two types of commonly used imaging agents, which have totally different binding 
regions of PSMA. The antibody encounter, J591 antibody, on the contrary, binds to an 
extracellular domain which is distant from the enzymatic pocket. Compared with the current 
standard imaging of bone scan and CT, PSMA targeted PET/SPECT imaging appears to have 
higher sensitivity and specificity. Currently, the new PSMA targeted SPECT imaging using 
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radionuclide such as radiohalogenated group like 18F, 123I, 124I or diagnostic radiometals like 
68Ga, 99mTc, 64Cu and therapeutic radiometals such as 177Lu. [18F]-DCFBC and [18F]-DCFPyL are 
the two comprehensively studied 18F PSMA targeted imaging tracers. 
 
Figure 1.7 Chemical Structure of [18F]-DCFPyL (left) and [18F]-DCFBC 
 
 
Figure 1.8 (a) Axial 18F-DCFBC PET and (b) PET/CT images through the pelvis of prostate 
cancer patient [15] 
 
Apart from radiohalogenated PSMA targeted small molecule inhibitors, radiometal-labeled 
radiotracers have also been studied. The use of different radionuclide has different function from 
diagnostic purpose to radiotherapy. 225Ac and 227Th are also two radionuclides which have 
therapeutic value transmitting 97% of their energy through alpha particle emissions. 177Lu is the 
beta-emitting radionuclide which has more favorable emission properties and other advantages 




1.4. Chemical Methodology for Radiolabeling 
1.4.1 Halogen Element Radionuclides (F, Br, I) 
Halogen group is a crucial element group for radionuclide – fluorine, chlorine, iodine. For the 
development of PET imaging radiopharmaceuticals, 18F is considered to be the most ideal 
radionuclides. 18F labeled PET imaging has a lower positron energy (0.64MeV) with shorter 
tissue penetration range (below 2.4 mm) in high specific activity. Moreover, the size of the 
fluorine atom is similar to hydrogen atom, which makes fluorine a good substitution for 
hydrogen atom. In the meantime, fluorine is the most electronegative element that can take 
participate in many reactions. 





The most successful approach to prepare high specific activity 18F radiotracer is based on 
nucleophilic fluorination reactions. The first category reaction involves the aliphatic nucleophilic 
substitution (SN2), while the second category reaction involves the aromatic nucleophilic 
substitution (SNAr). 
Nuclide half-life (hr) Decay mode Maximum Energy of β+ (MeV) 
18F 1.83 β+, EC 0.635 
123I 13.2 EC, γ  0.159 γ 
124I 100.8 β+, EC, γ 2.13; γ 
131I 192.8 β-, γ  0.6 MeV β-; 0.364 γ 
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1.4.2 Metal Radionuclides (Rb, Ga, In, Cu and Tc) 
Metal chemistry is another branch to be utilized for molecular imaging, which would enable us 
to develop new radiotracer based on β+ emitting radiometals. It gains edge over other imaging 
tracers with easy availability to conjugate biomolecules and ability to form imaging/therapy 
radiometal pairs. Some important radiometals for developing molecular imaging probes are 
gallium, indium, yttrium and some transition metals with coordination chemistry. Among the β+ 
emitting metallic nuclides, 64Cu (T½= 12.6 h), 66Ga (T½ = 9.45 h), 86Y (T½ = 14.74 h), and 89Zr 
(T½ = 3.27 days) are more appropriate for development of commercial PET 
radiopharmaceuticals with good transportation advantage. The specific labeling strategies using 
metal radionuclide will be discussed in further contents. 








1.4.3 Organic Radionuclides (C, N, O) 
11C, 13N and 15O are commonly used organic radionuclides for PET imaging tracer development. 
Carbon, nitrogen and oxygen are major elements in all natural organic molecules where we can 
Nuclide half-life (hr) Decay mode β (%) Emission 
64Cu 12.8 EC, β+, β- β+ (19), β- (40) 
66Ga 9.45 EC, β+  β+ (62) 
68Ga 1.14 EC, β+  β+ (90) 
86Y 14.74 EC, β+  β+ (34) 
90Y 64.08 β- β+ (93) 
89Zr 78.48 EC, β+  β+ (23) 
97Zr 16.8 β-, γ β- (100) 
111In 67.2 EC, γ  
99mTc 6.01 IT   
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engineer a natural biomolecule into a radiolabeled one. Among the three elements, there is no 
SPECT radiotracer available for this imaging modality. 
11C is the most successful radionuclide for developing radiotracer because it can be engineered to 
substitute a stable carbon of a molecule with minimal alteration of its biological properties. 
However, its short half-life around 20 minutes restricts its application because it requires on site 
production with cyclotron to prepare the radiotracer. [11C] CO2 is the first radiolabeled 
compound used to study photosynthesis in plants. After decades of researching, an increasing 
number of 11C labeled radiotracers have been developed for clinical studies. The most commonly 
used organic synthesis labeling strategies for 11C involves the alkylations of C, N, O and S 
nucleophiles with [11C] methyl iodide or methyl triflate.  
1.5 Nanoparticles on Molecular Imaging 
Nanoparticles are generally defined as particles with a diameter in the nanometer size range. In 
biomedical field, nanoparticles can be utilized as carrier, nanomedicine which interacts with 
cells. However, when the molecular imaging and the nanoparticles are conjugated to radiolabel 
nanoparticles, the field can be expanded into wide application in theranostics development. The 
multifunctional nanoparticles possess various function as multimodal imaging and therapy 
simultaneously [16]. 
1.5.1 Nanoparticles for Magnetic Resonance Imaging (MRI) 
For molecular imaging, the successful contrast agent development should have a high sensitivity. 
For nanoparticles, there are many ways to control the nanoparticles size, composition and its 
properties. The sensitivity of MRI can be highly improved by using contrast agent to modify the 
relaxation time of water protons where nanoparticles can be further incorporated. 
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The widely studied contrast agents for MRI are paramagnetic gadolinium complexes. It shows 
great success in detecting breakage of blood brain barrier (BBB), and other lesion or abnormal 
change in the brain [17]. However, the gadolinium-based contrast agent has several limitations 
such as low relaxivity, high dose injection, short circulation time etc, which may cause side 
effects [18]. Iron oxide-based contrast agents have been furthermore studied since it is safer 
contrast agent. The iron oxide nanoparticles are mainly cleared by macrophages and degraded in 
lysosomes which are stored as ferritin and can be used in various biological process in human 
body [19]. Except its good biocompatibility, iron oxide-based contrast agents also have higher 
sensitivity and easy manipulation of its size, composition [20]. 
Chapter 2: Synthesis, Cyclization and In Vitro Binding Study of Death 
Receptor 5 Targeted Peptides  
Cancer is characterized by abnormal cell proliferation and unregulated cell death. Clinically 
speaking, nowadays the most prevalent way to develop anticancer strategies is to eliminate 
cancer cell metastasis and induce cell apoptosis [21]. Tumor necrosis factor (TNF)-related 
apoptosis-inducing ligand, known as TRAIL, has a prominent ability to induce apoptosis in 
malignant cancer cells while pose no harms to majority of untransformed cells, which can be 
seen as a promising anticancer agent [22]. Apoptosis is an inherent and crucial biological process 
for maintaining cellular homeostasis, dysregulated apoptosis may induce disease such as cancer, 
autoimmune disorders [23]. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is 
able to bind Death Receptor 4 (DR4) and Death Receptor 5 (DR5), which are promising 
receptors for cancer imaging. With this promising property, TRAIL has been widely studied for 
cancer-related therapy and imaging.  Apoptosis is a common biological cell death process which 
is in a genetically regulated form. It is a crucial physiological process that remove unwanted cells 
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form multicellular organisms [24]. Colorectal cancer is one of the most frequently diagnosed 
cancer in United States, Death Receptor 5 (TRAIL-R2) shows a significant upregulation in 
colorectal cancer, which can be used as a useful biomarker for colorectal cancer imaging.    
2.1 TRAIL-induced apoptosis mechanism 
There are two principle routes to the activation of caspases, which the key feature of cell death 
signaling, namely the intrinsic pathway and the extrinsic pathways [25]. Death receptors would 
utilize the extrinsic pathway to provide death cues to the cells, while the chemotherapeutic 
agents would trigger the intrinsic pathway. Although there is no well-defined signaling 
pathways, increasing evidence shows that the two major pathways got a cross-talk [26]. TRAIL 
receptor is not the most powerful target since some tumor cells will use some regulators such as 
c-FLIP (blocking assembly of DISC), caspase-8, NF-κB, Akt to evade cell death signaling. The 
extrinsic pathway is activated by ligation of death receptor, adaptor proteins FADD will be 
recruited to the cytoplasmic tail of the receptor, then recruit procaspases 8/10, assembling into 
the death-inducing signaling complex (DISC). Next the procaspases 8 and 10 autocatalytically 
activate themselves. In a series caspase 3, 6, 7 are activated by caspase 9. The extrinsic pathway 
is independent of p53 activity as well as Bcl-2 or Bcl-xL. The other pathway is intrinsic pathway, 
which is also called mitochondrial pathway. Unlike extrinsic pathway, intrinsic pathway is 
activated through activities that is harmful to cells such as cytotoxic agents, cell distress and 
defective cell cycles, detachment from the extracellular matrix, hypoxia [27]. This pathway is 
triggered by the BCL2 superfamily, engaging a set of proapoptotic Bcl-2 members, the Bax, Bak 
or Bok to release factors cytochrome c and Smac/DIABLO [28]. Within the cytosol, cytochrome c 
binds APAF1, assembling into an apoptosome that recruits and activates caspase-9, then same as 
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activation of caspase 3, 6, 7. There is a convergence at both pathways, and clearly p53 appears to 
be a requirement for initiating death pathway [29].  
 
Figure 2.1 Extrinsic and intrinsic pathway of apoptosis [21] 
 
2.2 TRAIL in Liver and Central Nervous Disease 
Two other disease has been associated with TRAIL, Liver cirrhosis and neurodegenerative 
disease have been less focused and the main TRAIL research is on its effect on cancer therapy or 
imaging. Generally, mature neurons will last the lifespan of the organism [30]. While for 
neurodegenerative disease, there is an unbalanced cell death, which neuronal cell apoptosis 
occurs. TRAIL is present in the central nervous system which can induce apoptosis in brain cells. 
There are studies show that HIV-1-associated dementia, Alzheimer’s disease and multiple 




Figure 2.2. Possible role of TRAIL in neurodegenerative diseases [32] 
Liver fibrosis is a common chronic liver disease which will lead to liver cirrhosis and 
heptatocellular carcinoma, which is a major cause of death. When researchers take a deep look at 
the liver fibrosis, it has been shown that activated hepatic stellate cells (aHSCs) is the major cells 
that contribute to the liver fibrosis. Hence the basic strategy to contain liver fibrosis is to 
preserve quiescent HSCs and eradicate aHSCs. TRAIL, in this case, is an alternative strategy. 
Studies have shown that aHSCs is associated with an overexpression of death receptors and are 
sensitive to TRAIL-induced apoptosis. Therefore, Death receptors could be a potential target for 
actively imaging liver fibrosis and aHSCs apoptosis simultaneously.  
2.3 Development of DR5-binding peptides using phage display technique 
Speaking of types of molecular imaging agents, there are several different categories of them 
including small molecules, peptides, antibodies, protein fragments and nanoparticles. Due to the 
size difference of those molecular imaging agents, they have different pharmacokinetic and 
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binding properties [33]. Small molecules and peptides are two classes of molecular imaging agents 
which are crucial in this study. Small molecules play a significant role in molecular imaging. Its 
innate advantage of small size make it access to most of the targets from intracellular to CNS 
targets. And they face less unfavorable biodistribution issues than large molecular weight 
counterparts. It can cross the biological barriers, clear from the biological system in a relatively 
short period of time [34]. In this project, a library of five phage-displayed peptides has been 
determined as peptide-based imaging precursor that targets Death Receptor 5 and at the same 
time, it possesses therapeutic potential to trigger apoptosis. 
Solid phase peptide synthesis (SPPS) is a commonly used method to peptide synthesis in a fast 
and efficient way. A solid support which consists of small, polymeric resin beads functionalized 
with reactive amine group where peptide chains start to synthesize from C-terminus to N-
terminus.  
Phage display is a technology that can determine the sequence of high affinity peptide sequence 
by expressing foreign polypeptides as fusions to capsid proteins which is on the surface of 
bacteriophage [35]. After the screening of combinatorial peptide library against the receptors, the 
majority of the pharmaceuticals in market is efficacious by selectively interacting with 
membrane receptors, pharmacologically active small peptide ligands can be discovered with 
preferable properties than antibodies and proteins.  
Biopanning is a common method for obtaining a group of desired peptides from an initial 
bacteriophage pool. There are three major steps for the affinity selection: 1) introduce phages to 
an immobilized target; 2) isolate bound and unbound phages by washing; 3) elution of bounded 
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phages. Generally, in practice, several rounds for selection are necessary for the primary 
peptides.   
2.4 Cyclic peptides and cyclization strategies  
Cyclic peptides are peptides chains which formed by linking one end of the peptide structure and 
other with stable chemical bonds such as amide, disulfide, lactone etc. Various biologically 
active cyclic peptides are formed in N-to-C cyclization by amide bond formation. Cyclic 
peptides show better biological activity compared to the linear counterparts because of the 
conformational rigidity, which means the cyclic peptide has a decreased entropy term of the 
Gibbs free energy and large surface area for the exposed binding amino acid sequence, therefore 
it allows enhanced binding affinity towards the target receptor. Also, the structure of the cyclic 
peptide enables itself resistant to hydrolysis by exopeptidases due to the lack of amino and 
carboxyl termini. Since the cyclization constrains the flexibility of the peptide structure, it can 
even be resistant to endopeptidases.  
Cysteine (Cys), in this case, is a prevalent constituents of a peptide sequence to form disulfide 
bonds due to its thiol group on the side chain. A disulfide bond can give peptide higher rigidity 
and more stability. For instance, peptides are highly prone to metabolic degradation with short 
biological half-life [36]. The disulfide bonds formation is able to prolong its biological half-life by 
providing higher rigidity.  
In this study, iodine oxidation method has been used to cyclize the cysteine residues with ACM 
protecting group. The iodine oxidation method can remove the ACM group and form disulfide 
bond at the same time.    
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2.5 Labeling Strategies and Methodologies for Peptides 






Peptide radiopharmaceutical is under extensive studying in molecular imaging probe 
development for recent years. Peptide-based imaging probe is one of the special class of 
radiopharmaceuticals against small molecules and antibodies with distinct advantages. A lot of 
research literatures indicate that there are various receptors show high affinity towards both 
peptides and small molecules ligands. But still peptides are popular in developing imaging probe 
with the advantages of low molecular weight compared to antibodies, good tissue diffusion and 
easy chemical modification [37]. But when all potential radiopharmaceuticals are evaluated under 
clinical use, peptide also shows edges over other candidates on clearance kinetics, metabolic 
stability and easy radiolabeling [38]. Peptides are sequences of various amino acids linked 
together through amide bonds, the side chain of some types of amino acids is chemically active 
that can be used to radiolabel certain radionuclides. On the contrary, monoclonal antibodies, 
while it has potential to target tumor, relatively long circulating half-life, its poor tissue 
penetration loses its advantage over peptide candidates. 
Radionuclides Half-life Application 
123I 13.2 h SPECT imaging 
124I 4.2 days PET imaging 
125I 59.4 days 
Physiological process in long period 
(in vivo study)  
131I 8.0 days SPECT imaging & therapy 
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There are various radionuclides mentioned above that can be chosen for radiolabeling. In order 
to design an efficacious radiopharmaceutical, there are some general considerations with respect 
to the selection of a label. First and foremost, it depends on the application of your radiolabeled 
compound. Radiopharmaceutical is a special class of drugs, because for imaging purpose, the 
labeled moiety shows no biological activity. The radionuclides that conjugate to a bioactive 
biomolecule can alter its properties to hinder an effective binding. An efficacious imaging probe 
is to demonstrate similar pharmacokinetics, sensitivity and specificity compared to that of non- 
labeled molecules [39] [40].  
The half-life of the radionuclides is a crucial consideration for selecting a label. The most desired 
radionuclide has an appropriate half-life that enables the tracer accumulate in the targeted spot 
before losing its desired radioactivity. Half-life of undesired radionuclide either is too long or too 
short. For in vivo study, long half-life radionuclide is not an issue, but for clinical trials, it poses 
threat on dosing limit. Short half-life radionuclide will lose its optimal radioactivity before it 
reaches the targeted tissue.   
Appropriate labeling methods is also a paramount factor for desired imaging. Different labeling 
method may have different radio yield and radioactivity. If the tracer will be utilized for clinical 
use, the high radiolabeling yield must be maintained. On the other hand, if the target tissue 
expression is low, the radionuclide should have higher specific radioactivity. Another factor that 
need to be considered is the influence of the labeling method on how it will change the tracer’s 
targeting properties, which will affect the biodistribution.  
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2.5.1 Halogen-labeled peptide radiopharmaceuticals methods 
For radioiodination of peptides, there are two general synthetic methods: direct radioiodination 
by electrophilic substitution and indirect radioiodination by chemical conjugation. Among the 
various iodine isotopes, 123I, 124I, 125I and 131I are widely used for different imaging modalities. 
123I is a perfect candidate for SPECT imaging, γ-emitting 131I can be used for SPECT imaging. 
For direct radiolabeling of iodine radioisotopes, the labeling target for the peptide is the tyrosine 
and histidine residues where electrophilic substitution happens in a mild condition. Radioiodide 
is oxidized to form electrophile *I+ by oxidizing agent such as chloramine T, and N-
halosuccinimides. Then σ-complex is formed when *I+ attacks the aromatic rings of tyrosine 
which is electron-rich. And the hydroxyl group, which is electron-donating, stabilize the σ-
complex structure. However, the direct radioiodination is viable only when the peptide has 
tyrosine and histidine residues. Also, the enzyme tyrosine deiodase will happens when the iodine 
will be detached and accumulate in the thyroid, which is toxic in vivo.  
Figure 2.3. Chemical structure of prosthetic groups for radioiodination of peptides (I* stands for 
multiple radioisotopes for iodine) 
18F is a common radionuclide for PET imaging, however, it is impossible to label 18F onto a 
molecule in a mild condition via nucleophilic substitution reaction because the it is reacted in a 
high temperature and strong bases condition which will destroy the peptide structure [40]. 
Prosthetic group is often used for introducing 18F onto a molecule. First, the 18F is introduce on 
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prosthetic group, then simple reaction can link radiolabeled prosthetic group onto the 
biomolecules by amine, alkyne or azide groups, etc. [18F] SFB and [18F] NPFP are two successful 
prosthetic groups that use reactive amine group for coupling reaction with good yield and stable 
biological properties [40]. Various [18F] fluorinated prosthetic group reactions are conducted 
through thiol-maleimide reaction. Chemoselective conjugation methods using aldehydes, alkyne 
and azide derivatives labeled with 18F seems more suitable and efficient for clinical applications. 
 
Figure 2.4. Chemical structure of prosthetic groups for fluorination of peptides 
 
2.5.2 99mTc-labeled peptide radiopharmaceuticals method 
99mTc is the most frequently used radionuclide in nuclear medicine with several advantages such 
as ideal nuclear physical properties, easy commercial availability, low production cost and rich 
labeling chemistry. Most 99mTc complexes are in the oxidation state of +V, while most 99mTc 
complexes eluted from the generator are in 99mTcO4
-, a +VII oxidation state. Therefore, reducing 
agents such as Na2S2O4, SnCl2 can be used to reduce it to +V oxidation state. The most 
commonly used strategy is postconjugation strategy, which means a bifunctional chelator is first 
conjugate to the peptide, then the 99mTcO4





Figure 2.5. Chemical structure of chelators for the labeling of peptides with 99mTc 
Another useful strategy is label with the organometallic [99mTc(CO3)]
 + core. The 99mTc 
tricarbonyl approach can be used to develop radiopharmaceuticals with the organometallic 
precursors fac-[99mTc(CO)3(H2O)3]. 
99mTc-tricarbonyl complexes are formed with a tridentate 
BFC conjugated peptide, such as (Nα-His) Ac or picolylamine diacetic acide (PADA) which 
show better stability in vivo, compared to mono and bidentate ligands such as histidine [40]. 
2.5.3 Radiometal labeling method 
Among the radiometal labeling, radionuclide such as 111In, 67/68Ga, 86/90Y, 177Lu and 64/67 Cu are 
the most commonly used radionuclide for peptides. Hard and soft Lewis acids and bases theory, 
also known as HSAB concept, hard Lewis acids (Ga3+/In3+) can form thermodynamically stable 
complexes with hard ligands containing nitrogen and oxygen donor. DTPA is one of the 
chelators for labeling 111In with fast labeling kinetics. Another macrocyclic chelator DOTA can 
be used to chelate divalent and trivalent radiometals such as Ga3+, In3+, Y3+, Lu3+ and Cu2+, 
which can form thermodynamically and kinetically stable complexes. NOTA is the most 
favorable chelator for Ga labeling of peptides with higher complex stability than DOTA 
counterparts due to their cavity size difference. For larger size radiometal ions such as Yttrium, 
their complexes require higher coordination numbers of 8 or even 9. Due to the favorable 
pharmacokinetic profiles and appropriate cavity size, DOTA derivatives have been used for the 
90Y and  
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177Lu labeling, which forms a more stable complexes than acyclic chelating agents TETA.  
 















2.6 Experimental Section: 
Table 2.1 Peptide sequence of the five DP5 targeted peptides 
In this study, a library of five phage displayed peptides has been determined as peptide-based 
imaging precursor for Death Receptor 5 and apoptosis simultaneously. The unlabeled linear  
peptide is prepared for future characterization on its therapeutic potential, the cyclized peptide is 
prepared to test whether cyclization can enhance the binding affinity and enhanced biological 
half-life in vivo.  
2.6.1 Materials and methods: 
2.6.1.1 Materials. All Fmoc amino acids and cysteine preload Wang resin were purchased from 
Chem-Impex int’l Inc.. All other reagents such as DMF and TFA were purchased from vwr, 
honeywell and sigma-aldrich.  
2.6.1.2 DR5 peptide synthesis. All peptides were synthesized using standard 9-
fluorenylmethoxycarbonyl (Fmoc) solid phase synthesis techniques. The peptides were 











































synthesized on a 0.05 mmol scale using Liberty Blue automated microwave peptide synthesizer 
(CEM, Matthews, NC, USA). Fmoc deprotection was followed using 20% piperidine in DMF 
solution for multiple washes. Completed peptides were cleaved from the solid support using a 5 
ml mixture of TFA/TIS/H2O in a ratio of 95:2.5:2.5 for 3 hrs. Excess TFA was removed by 
blowing air, the remaining peptide solution was triturated with cold ethyl ether to precipitate the 
crude peptides, and they were further phase-separated by centrifuge (Megafuge 16, Thermofisher 
Scientific, Waltham, Massachusetts, USA) in 4500rpm for 5 min, and the ethyl ether was 
discarded and the rest peptide was air-dried and kept in the vacuum chamber for 3 hours.  
2.6.1.3 Cyclization Reaction. The cyclic peptide sequence is same compared with the linear 
one, however, the difference is on the protecting group, for linear peptide, the protecting group 
for cysteine is trityl (Trt), while for the cyclic peptide, the protecting group is Acetamidomethyl 
(ACM). The cyclic peptides were cyclized in a filtered-capped syringe. The crude peptides 
without resin cleavage was transferred to a filter syringe rinsed with 3 ml DMF. Iodine solids 
were dissolved in 2 ml DMF/H2O (ratio of 4:1). The peptides were treated with I2 solution and 
shake for 1 hour. After the shaking, separate the resin and solution by filter, then wash the 
peptide resin with DMF for three times, then wash the peptides with 2% ascorbic acid for three 
times, wash them with DMF and dichloromethane respectively. The cyclic peptide resins were 
cleaved using a 5 ml mixture of TFA/TIS/H2O in a ratio of 95:2.5:2.5 for 3 hrs. Excess TFA was 
removed by rotary evaporator, cold ethyl ether was added to precipitate the crude peptides, 
which were collected and dried under vacuum for 1 hour.  
2.6.1.4 Peptide purification. All the peptides were purified by preparative RP-HPLC (Agilent 
Technologies, Santa Clara, CA, USA) equipped with a fraction collector. The separations were 
preformed using C18 column (Luna, 100 Å, 10 μm, 250×10 mm) at 25℃ with monitoring 
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wavelength at 220 nm. The DP1-4 linear and cyclic peptides were all dissolved in 2 ml 20% 
acetonitrile in water. A water/acetonitrile gradient of 15% - 80% was run for 30 min containing 
0.1% TFA as eluent at a flow rate of 10 ml/min. For DP5 linear and cyclic peptides, they were 
dissolved in 2 ml 50% acetonitrile in water and separated with a water/acetonitrile gradient of 
45% - 80% in 30 min containing 0.1% TFA as eluent with 10 ml/min flow rate. Desired fractions 
were collected, and then concentrated. Peptides were freeze-dried on lyophilizer (FreeZone -
105°C, Labconco, Kansas City, MO, USA). 
The monitored wavelength is 220 nm and the threshold is 200 in a peak based collection mode. 
2.6.1.5 LCMS characterization. Dissolved the lyophilized peptide in 200 μL water, and prepare 
50 μL of concentrated sample solution to injection vials. The molecular weight of each peptide 
was characterized by 6120 Quadrupole LC/MS (Agilent Technologies, Santa Clara, CA, USA). 
All the samples were run in a water/acetonitrile gradient of 10%-90% (containing 0.1% TFA) in 
10 min with the flow rate of 0.8 ml/min. No fraction needs to be collected and the desired 
situation is a single peak in the liquid chromatography diagram to identify molecular mass.  
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2.7 Result and discussion 
 
Figure 2.1 FACS analysis of DP peptides for binding to DR5 expressing HCT116 cells. 
 
The HPLC purification data is listed in Appendices. All the peak above the threshold were 
collected as potential desired peaks and concentrated for LCMS characterization on its molecular 
weight. The DP1 to DP4 peptides are highly hydrophilic therefore the retention time is relatively 
short compared to DP5 peptides based on the gradient of 15%-80% MeCN in 30 min.  
As the flow cytometry data indicated above, the formation of disulfide bond has no significant 
influence on its binding affinity of DP1 peptide. While comparison between DP2 linear peptide 
and DP1 linear peptide shows that DP2 peptide has better binding affinity than DP1 peptide.  
2.8 Future perspectives: 
In the future, all the five fluorescent-labeled DP linear peptide and cyclic peptide will be 
synthesized and tested on flow cytometry to compare the binding affinity, then one or two 
peptides with the highest binding affinity will be screen out for future radiolabeling with DOTA 
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on chelating radiometals or prosthetic group on 18F or radioiodinated isotopes such as 125I. In the 
meantime, the unlabeled peptide will be used to test its therapeutic potential on whether it has the 
same biological function to trigger cell apoptosis signal.    
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4. Appendices  
Appendix 1: HPLC chromatogram and Mass Spectra of DP1 linear unlabeled peptide 
 
Purification gradient: A water/acetonitrile gradient of 15% - 80% was run for 30 min containing 




The mass spectrum indicates a base peak at m/z 511.5 assuming the peptide ions are most 
abundant in the 2+ charge state, and protonated [M+H] +, the peak of [C42H81N14O11S2]
 + peak 





Appendix 2: HPLC chromatogram and Mass Spectra of DP2 linear unlabeled peptide 
 
Purification gradient: A water/acetonitrile gradient of 15% - 80% was run for 30 min containing 
0.1% TFA as eluent at a flow rate of 10 ml/min.  
 
The mass spectrum indicates a base peak at m/z 548.0 assuming the peptide ions are most 
abundant in the 2+ charge state, and protonated [M+H] +, the peak of [C43H84N17O10S3]
 + peak 






Appendix 3: HPLC chromatogram and Mass Spectra of DP4 linear unlabeled peptide 
 
Purification gradient: A water/acetonitrile gradient of 15% - 80% was run for 30 min containing 
0.1% TFA as eluent at a flow rate of 10 ml/min.  
 
The mass spectrum indicates a base peak at m/z 526.0 assuming the peptide ions are most 
abundant in the 2+ charge state, and protonated [M+H] +, the peak of [C41H76N15O11S3]
 + peak 







Appendix 4: HPLC chromatogram and Mass Spectra of DP3 linear labeled peptide 
 
Purification gradient: A water/acetonitrile gradient of 15% - 80% was run for 30 min containing 
0.1% TFA as eluent at a flow rate of 10 ml/min.  
 
The mass spectrum indicates a base peak at m/z 708.4 assuming the peptide ions are most 
abundant in the 2+ charge state, and protonated [M+H] + with mass of 1416.4 is observed. The 









Appendix 5: HPLC chromatogram of DP3 cyclic labeled peptide 
 
 
Purification gradient: A water/acetonitrile gradient of 15% - 80% was run for 30 min containing 
0.1% TFA as eluent at a flow rate of 10 ml/min.  
 
Appendix 4:  Mass Spectra of DP1 linear labeled peptide 
 
The mass spectrum indicates a base peak at m/z 690.9 assuming the peptide ions are most 
abundant in the 2+ charge state, and protonated [M+H] + with mass of 1380.7 is observed. The 





Appendix 5:  Mass Spectra of DP2 cyclic unlabeled peptide 
 
 
The mass spectrum indicates a base peak at m/z 547.0 assuming the peptide ions are most 
abundant in the 2+ charge state, and protonated [M+H] + with mass of 1094.7 is observed. The 
DP2 cyclic unlabeled peptide has purity over 90%.  
 
Appendix 6:  Mass Spectra of DP2 linear labeled peptide 
 
 
The mass spectrum indicates a base peak at m/z 727.7 and 485.1 assuming the peptide ions are 
abundant in the 2+ charge state and +3 charge state. The DP2 linear labeled peptide has purity 
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• Basic characterization methods related to Gene Delivery are well understood 
 
Bachelor’s thesis：Synthesis of 2D MoS2-peptide nanohybrid materials and study of its 
application                     Dec. 2015- Graduation          
                                                                                     
• Two-Solvent Grinding-assisted Liquid phase exfoliation method is used to exfoliate bulk MoS2 
into few layered 2D MoS2 nanoflakes: N-methyl-2-pyrrolidone (NMP) and ethanol were used to 
exfoliate MoS2 bulk materials 
• Ionic Liquid BMIMPF6 (IL) is used as solvent to assist exfoliation process 
• Synthesis of self-assembled peptide nanofibers (sequence: 
RGDAEAKAEAKAEAKAEAKCCY) 
• During the exfoliation, there are defects on the surface of 2D MoS2 layers, using thiol 
chemistry to functionalize the MoS2.  
• Characterization of 2D MoS2 nanoflakes by TEM, HRTEM, AFM 





Lab Training on Biomaterials 
• Acylation of Gelatin and preparation of enteric microcapsules  
• Preparation and characterization of microcapsules by w1/o/w2 double emulsion method   
• Lab training on cell culture 
• preparation of pre-adsorption of PNIPAM on polystyrene(PS) microsphere and study of its 
effect on non-specific protein adsorption of lysozyme  
• specific local test of blood coagulation of materials surface by coagulometers: prothrombin 
time(PT) and Activated partial thromboplastin time(APTT) are tested   
• Polymerization of UV curable resin  
 
Study of the Application of Polyurethane in Biomaterials                                       Spring 2014                                                                        
•  Conducted synthesis experimentation of polyurethane 
•  Weissenberg effect was observed; improved hands on ability in chemical experiment 
•  Became acquainted with polymer physics and polymer chemistry 
 
SKILL & INTERESTS                                                                               
•  Technical Skills: proficient in C, Origin, Chemoffice, Excel, Word, PowerPoint, Photoshop, 
etc.; 
•  Interests: Music, basketball, badminton, table tennis, travel 
 
 
 
